May 4, 2026 | Biosimilar, Cost Savings, MedBen Rx, Rx Costs, Rx Spending, Savings
Specialty drugs account for more than half of total drug spend and are often the largest cost driver for employer pharmacy plans. A recent BenefitPRO article points to biosimilars as a practical solution — and for MedBen Rx clients, the...
Mar 23, 2026 | Clinical guidance, Drug costs, MedBen Rx, Rx Advertising, Rx Costs
Heavy direct-to-consumer advertising of high-cost medications is fueling patient demand and placing added pressure on physicians to prescribe the drugs that patients recognize — even when lower-cost alternatives may be just as, or more, effective. The scale of this...
Feb 23, 2026 | Biosimilar, Cost Savings, MedBen Rx, Rx Costs, Rx prices, Rx Spending, Savings, Specialty Drugs
Specialty medications continue to dominate pharmacy spend, now accounting for 52% of all U.S. pharmaceutical sales, according to a recent report from the Healthcare Distribution Alliance. With costs often reaching tens — or even hundreds — of thousands of dollars per...
Jan 12, 2026 | Acquisition Cost Index (ACI), Biosimilar, Brand Name Drugs, Drug costs, High-value formulary, MedBen Rx, News, Patient assistance program, Pharmacogenomics, Rx Costs, Rx prices
Pharmaceutical manufacturers are planning to raise list prices on at least 350 brand-name medications in the United States beginning in 2026, up from 250 drugs last year, according to new data from health care research firm 3 Axis Advisors. These increases reflect...
Dec 15, 2025 | GLP-1s, MedBen Rx, Medicaid, Pharmacies, Weight loss, Weight loss drugs, Weight management
In recent months, a growing number of U.S. states have pulled back on covering GLP-1 medications for obesity under their Medicaid programs, even as the drugs remain broadly covered for diabetes. A recent KFF survey shows that while 16 state Medicaid programs still...
